Odense C

• A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10 … Recruiting
  2023-507353-15-00 5 2024-09-10 idiopathic pulmonary fibrosis (IPF)
• OPTIMAL DIURETIC THERAPIES FOR ACUTE HEART FAILURE WITH VOLUME OVERLOAD Recruiting
  2024-510633-17-00 5 2024-09-05 acute heart failure
• A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-506704-14-00 4 2024-09-04 Moderately to Severely Active Crohn's Disease
• Self-administration of subcutaneous Elranatamab in the patients’ homes (ERICA) Recruiting
  2023-507876-30-00 4 2024-09-04 Multiple Myeloma
• Safety and efficacy of oral semaglutide in hyperglycaemic patients after renal transplantation Recruiting
  2023-504159-29-01 4 2024-09-03 Hyperglycaemia after renal transplantation
• Improving diagnostics in cervical dysplasia Recruiting
  2024-517151-12-00 6 2024-09-01 Patients are either or both HPV positive and has cervical cell changes
• A study to assess the efficacy and safety of OATD-01 for the treatment of active pulmonary sarcoidosis. Recruiting
  2023-506642-23-01 4 2024-08-28 Active Pulmonary Sarcoidosis
• PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE INTENSITY VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH INTEGRATION OF … Recruiting
  2023-510415-19-00 4 2024-08-28 Acute Myeloid Leukemia
• An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study) Recruiting
  2023-508444-22-01 1 2024-08-26 Chronic hepatitis B infection
• Palliation of Dyspnea and Cough using Morphine in patients with Fibrotic Interstitial Lung Disease Recruiting
  2023-503700-81-00 6 2024-08-23 Fibrotic Interstitial Lung Disease
• Short course antibiotic treatment of Gram-negative bacteremia: A multicenter, randomized, non-blinded, non-inferiority interventional study Recruiting
  2024-514900-16-00 6 2024-07-25 Gram-negative Bacteremia
• HEMODIALYSIS AND ANTIBIOTIC PROPHYLAXIS Recruiting
  2024-515001-26-00 6 2024-07-25 Blood poisoning in patients with renal failure treated with hemodialys
• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt … Recruiting
  2023-507684-19-00 5 2024-07-24 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
• Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting
  2023-504962-52-00 5 2024-07-10 Triple negative breast cancer.
• Intrapleural Fibrinolysis and DNase versus VATS for the treatment of pleural empyema: a randomized, controlled trial Recruiting
  2024-513596-40-00 6 2024-06-28 Pleural empyema
• IMPACT – the introduction of mycotic prophylaxis at cystectomy trial. Recruiting
  2023-506226-36-00 6 2024-06-23 Fungal infection
• A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants … Recruiting
  2022-501697-19-01 5 2024-06-18 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
• The effect of oral Semaglutide on bone turnover in patients with T2D: a randomized placebo-controlled clinical trial (SOBER II) Recruiting
  2023-505959-45-00 4 2024-05-31 Type 2 diabetes
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• A trial to learn if volrustomig is safe and efficacious in women and young adults with locally advanced cervical cancer. Recruiting
  2023-504374-38-00 5 2024-04-12 Locally advanced cervical cancer
• HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa … Recruiting
  2022-500305-40-00 9 2024-04-10 Small Lymphocytic Lymphoma
• A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch … Recruiting
  2023-504899-25-00 5 2024-04-04 Metastatic castration resistant prostate cancer
• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 5 2024-04-04 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
• SGLT2 inhibitor TrEatment iN patients awaiting cOronary arTery bYpass surgery to reduce Post-opErative atrial fibrillation and kidney injury … Recruiting
  2023-505375-75-00 5 2024-04-04 Onset of Atrial Fibrillation and Acute Kidney Injury after coronary ar

Showing 169–192 of 457 trials